Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,018 total articles
Shane Kapral, Deputy CFO of TKO Group Holdings, executed a sale of 1,851 shares of Class A Common Stock worth nearly $375,000 over a two-day period, accompanied by a simultaneous exercise of stock options. Recent corporate developments include an upward revision of TKO’s stock price target, expansion of its credit facility, and strategic partnershi…
Janet Dillione, a director at CorMedix Inc, sold 10,000 shares in late January 2026, executing transactions between $6.85 and $6.90 per share, totaling $68,800. Post-sale, Dillione retains direct ownership of 38,473 shares. The company disclosed preliminary Q4 2025 net revenue of approximately $127 million, with 2025 fullyear revenue at $310 millio…
Jeffrey Richart Geygan, serving as interim CEO at Rocky Mountain Chocolate Factory, Inc., acquired an additional 11,300 shares, enhancing his overall stake in the company. This insider purchase coincides with recent quarterly financial disclosures that show revenue growth tempered by profitability issues and a modest decline in sales. With the stoc…
Global Value Investment Corp, owning a 10% stake in Rocky Mountain Chocolate Factory, acquired an additional 11,300 shares at $1.9781 each, totaling over $22,000. This move comes even as Rocky Mountain Chocolate Factory reports ongoing financial challenges, including weak profitability metrics and a modest market capitalization. Recent quarterly ea…
Pliant Therapeutics' CFO, Keith Lamont Cummings, sold over 24,000 shares in January 2026, a move occurring alongside a significant decline in the company's share price over the past year. Despite financial setbacks, the company reported promising clinical trial results and notable executive changes.
Lily Cheung, Chief Human Resource Officer at Pliant Therapeutics (NASDAQ:PLRX), sold 7,534 shares worth approximately $9,643 in late January. Concurrently, the company shared positive interim Phase 1 data for its investigational cancer therapy and disclosed recent executive movements, highlighting ongoing changes at the firm.
Bernard Coulie, President and CEO of Pliant Therapeutics, recently sold shares to cover tax liabilities tied to employee stock vesting, coinciding with notable clinical trial advances and executive shifts within the company. These developments highlight ongoing operational and strategic adjustments affecting stakeholders across the pharmaceutical s…
Natera Inc's Chief Financial Officer, Michael Burkes Brophy, sold over 60,000 shares recently worth approximately $14.6 million. Concurrently, the company revealed encouraging fourth-quarter 2025 financial results, significant test volume increases, and advancements in cancer diagnostics through collaborative trials and new AI models enhancing recu…
Minnie Kuo, Chief Operating Officer of Pliant Therapeutics, recently sold 6,917 shares of the company’s stock to satisfy tax obligations related to vested restricted stock units. This sale, executed throughout January 20-22, 2026, totaled $8,853 and reflects a weighted price range between $1.245 and $1.33 per share. Pliant’s stock has experienced a…
Natera’s CEO Steven Leonard Chapman sold over seventy-three thousand shares worth approximately $17.2 million to cover tax liabilities from vested restricted stock units. Amid this, the company reported strong fourth-quarter 2025 financials exceeding analyst estimates and advanced its oncology and genetic testing pipeline through collaborations and…
Owlet, Inc.'s President and CEO Jonathan Harris sold 2,311 shares of the company's common stock on January 20, 2026, generating proceeds exceeding $30,000. Concurrently, Owlet is pushing forward with multiple initiatives including insurance partnerships and international product launches to enhance its pediatric health monitoring profile.
Casey O’Connor, Stitch Fix’s Chief Legal Officer, sold over $725,000 worth of company stock through a scheduled trading plan in January 2026. Concurrently, the company reported revenue exceeding forecasts and extended its credit agreement maturity, signaling positive financial movements despite client declines.
Owlet, Inc.'s Chief Financial Officer Amanda Crawford recently divested a modest portion of her shares, totaling $2,439, primarily to address tax and fee commitments linked to restricted stock units. This transaction comes as Owlet's stock maintains robust gains over the past year. Meanwhile, the company is actively broadening its market footprint …
Daniel Rabinowitz, Natera's SEC and Chief Legal Officer, sold nearly $4.6 million worth of company stock over two days in January 2026 while also acquiring shares through restricted stock unit exercises. This insider activity follows Natera's impressive preliminary fourth-quarter financial results and announcements of innovative developments in can…
Solomon Moshkevich, President of Clinical Diagnostics at Natera, recently sold over 23,400 shares of the company's common stock between January 20 and 21, 2026, generating proceeds of approximately $5.5 million. The sales were made under a pre-arranged trading plan to cover tax liabilities from vested Restricted Stock Units. Natera’s shares have ga…
John Fesko, serving as President and Chief Business Officer of Natera, Inc., recently completed the sale of over 18,000 shares of the company's stock, raising approximately $4.26 million. These transactions were part of a prearranged plan intended to meet tax liabilities related to vested equity awards. Concurrently, Natera reported strong prelimin…
Sheena Jonathan, co-founder of Natera, Inc., executed sales of 3,664 shares of the company's common stock worth approximately $1.44 million over two days in January 2026. The transactions occurred alongside the company's disclosure of promising preliminary fourth-quarter results, a strategic collaboration with Exelixis for a colorectal cancer trial…
James Fu Bin Lu, who holds a 10% stake in Grindr Inc., completed a substantial sale of 600,000 shares valued at over $7.2 million in mid-January 2026. The sales unfolded over three days, indicating a gradual divestment. Concurrently, Grindr has strengthened its financial position by expanding its credit facility from $350 million to $600 million an…
Viant Technology Inc.'s CEO Timothy Vanderhook conducted insider sales of Class A Common Stock totaling 12,500 shares via Capital V LLC over three days in January 2026, while the company reported better-than-expected third-quarter results and announced a strategic alliance with iHeartMedia. Despite the insider sales, Viant has maintained a solid fi…
Christopher Vanderhook, Viant Technology's COO and substantial shareholder, conducted an indirect sale of 12,500 Class A shares, generating proceeds of approximately $153,129. Concurrently, the company reported impressive Q3 2025 financial results and unveiled a new collaboration with iHeartMedia to enhance programmatic advertising capabilities acr…
Capital V LLC, holding a 10% stake in Viant Technology Inc., sold 37,500 shares of Class A Common Stock totaling approximately $459,389 between January 20 and January 22, 2026. Viant Technology recently reported robust third-quarter earnings surpassing analyst estimates and unveiled a programmatic advertising partnership with iHeartMedia. Analyst f…
Coreweave's Chief Development Officer, Brannin McBee, recently sold 130,345 Class A shares valued at approximately $12.5 million, according to filings from January 20, 2026. The sales were undertaken through a Rule 10b5-1 trading plan and coincided with company developments including enhanced AI platform offerings and financial adjustments. Despite…
CoreWeave's Chief Development Officer Brannin McBee sold over 34,000 shares totaling approximately $3.3 million under a structured trading plan, reflecting a complex stock position management amid significant company developments including loan amendments and AI technology integration plans. The stock has experienced substantial annual gains despit…
Abeona Therapeutics Chief Executive Officer Vishwas Seshadri executed a sale of nearly 70,000 shares for $372,267 to address tax liabilities linked to restricted stock awards. The biopharmaceutical firm also reported a better-than-expected quarterly earnings performance, while making strategic appointments and expanding its gene therapy treatment f…
Joseph Walter Vazzano, CFO of Abeona Therapeutics Inc, sold over 18,600 shares to meet tax obligations following restricted stock vesting. This insider sale follows the company’s positive third-quarter financial report and advancements in its gene therapy treatment offerings. Industry analysts present mixed price targets, reflecting ongoing operati…
